ISCT Webinar: Forecasting CoG for Cell Therapies to Guide Manufacturing Process Development
Organized by the ISCT Business Models and Cost of Goods (CoG) Subcommittee
Sponsored by Pall Life Sciences
Date: Tuesday, April 26, 2016
- Bill Milligan, SVP Corp Dev & International Bus.Dev, Steminent BioTherapeutics Inc, Canada (ISCT Business Models and CoG Subcommittee Chair)
- Tom Brieva, PhD, Director, New Product Platforms, Celgene Cellular Therapeutics, USA (ISCT Process and Product Development Subcommittee Member)
- Suzanne Farid, PhD, Professor, Biochemical Engineering, University College London, UK (ISCT Business Models and CoG Subcommittee Member)
About the Webinar:
Forecasting CoG for cell therapy products is an essential planning discipline for managing the cost of manufacturing during process development. In this session, our speakers from Celgene and UCL will introduce tools and share their experience to help you increase your knowledge of the importance of forecasting your manufacturing CoG. This can help to guide your manufacturing process development decisions which can influence the CoG, ultimate selling price and sustainability of your cell therapy product in the market. This webinar will address forecasting CoG with respect to both autologous and allogeneic manufacturing process development projects.
- Forecasting CoG: Methodology to help you to gain a better understanding of current costs and to predict future costs.
- Autologous CoG: How to anticipate where your cost challenges are for autologous projects and how they can impact on your forecasted CoG.
- Allogeneic CoG: Understanding key process economic drivers for allogeneic projects and their impact on your forecast CoG and achievable margins on sales.
- Target product pricing: How you can use a target product price to determine what your goals for manufacturing process costs will be and how each step in the process must be optimized to achieve your forecast.
- Process change costs: Influence of process changes to more cost-effective technologies on drug development costs and overall profitability.